Artesunate

Artesunate is indicated for the initial treatment of severe malaria. The World Health Organization recommends artesunate as first line treatment for severe malaria. Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin]. Artesunate was granted FDA approval on 26 May 2020.

IUPAC Name: 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
CAS No: 88495-63-0
Synonyms: Artesunate
Artesunic acid
Arsumax
Dihydroqinghasu hemsuccinate
88495-63-0
Arinate
Artesunatum
Artesunato
Plasmotrin
Molecular Formula: C₁₉H₂₈O₈
Molecular Weight: 384.4 g/mol